Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolcapone for Cognitive Dysfunction in TBI/ABI and NCD
NCT02652598Phase 2Unknown
- Sponsor
- Sheppard Pratt
- Start
- Nov 2015
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tolcapone in traumatic brain injury (TBI), acquired brain injury (ABI), neurocognitive disorder (NCD), sponsored by Sheppard Pratt. Status: unknown.
02
Drugs
tolcapone
03
Conditions
traumatic brain injury (TBI)acquired brain injury (ABI)neurocognitive disorder (NCD)
Beyond the preview
Go deeper on NCT02652598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02652598.